Baricitinib: From Rheumatoid Arthritis to COVID‐19

Baricitinib is a JAK1/2 inhibitor that was first approved for treating moderate to severe rheumatoid arthritis (RA) but that later showed considerable efficacy in the control of exaggerated inflammatory responses that occur in a wide range of diseases. There is a growing body of evidence, obtained f...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Clin Pharmacol
Main Authors: Assadiasl, Sara, Fatahi, Yousef, Mosharmovahed, Banafsheh, Mohebbi, Bahareh, Nicknam, Mohammad Hossein
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley and Sons Inc. 2021
Fag:
Review
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8250677/
https://ncbi.nlm.nih.gov/pubmed/33870531
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1874
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker